好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cross-talk between Multiple Sclerosis (MS)-relevant B cell subsets and myeloid cells: potential contribution to the CNS-compartmentalized inflammation associated with disease progression
Multiple Sclerosis
P2 - Poster Session 2 (5:30 PM-6:30 PM)
15-083

To assess potential cross-talk between multiple sclerosis (MS)-implicated B cell subsets and microglia/macrophage.

The subpial cortical injury of MS (involving demyelination, neuronal loss and microglial activation) is now thought to represent an important substrate of progressive disease pathology. Of growing interest is the possibility that meningeal inflammation (particularly B cells) contribute to this injury through soluble-factor release. We previously reported that MS patients harbor abnormally increased pro-inflammatory B cells (Beff) which, in the periphery of patients, appear to foster pro-inflammatory responses of circulating myeloid cells. Here we considered whether bidirectional interactions between B cells and resident microglia (and/or infiltrating macrophage) could contribute to propagating CNS-compartmentalized inflammation and injury. 

Survival and activation of human B cells were assessed (flow cytometry) following in vitro exposure to conditioned-media of pro-inflammatory (M1) or anti-inflammatory (M2a&M2c) human-derived microglia and macrophage. In turn, microglia and macrophage were exposed to soluble products of Beff or regulatory (Breg) B cells, isolated (Miltenyi MACS) from MS patients and matching healthy controls (HC); myeloid cell cytokine secretion (ELISA), phenotype and phagocytic capacity (flow cytometry) were subsequently assessed.

M1 microglia and macrophage supernatants substantially induced B-cell expression of CD86 and CD95 (n=9; both p<0.0001), while M2c products mediated B-cell death (n=7, p<0.0001). In turn, Beff supernatants increased microglia/macrophage expression of CD80 (n=4-5, p=0.07/p=0.02) and the pro-inflammatory cytokine IL-12, IL-6 and TNF (n=6, p=0.03, p=0.01, p=0.0012 respectively for microglia; n=3-6, p=0.0004, p=0.01, p=0.002 respectively for macrophage), while down-regulating their IL-10 production (n=6, p=0.0024 microglia; n=3-6; p=0.002 macrophage). Breg supernatants enhanced microglia/macrophage expression of TREM-2 (n=4-5, p=0.03/p=0.03). Beff supernatants inhibited, while Breg supernatants induced microglia/macrophage phagocytic function (n=4-6, p=0.01/p=0.03). 

Bidirectional cross-talk between MS-relevant B cell subsets and microglia/macrophage may sustain ongoing cascades of CNS-compartmentalized inflammation and injury, potentially offering new therapeutic targets for future development in progressive MS. 

Authors/Disclosures
Hanane Touil, PhD (McGill - University of Pennsylvania)
PRESENTER
No disclosure on file
Rui Li (McGill University) Mr. Li has nothing to disclose.
Leah Zuroff, MD (Hospital of the University of Pennsylvania) Dr. Zuroff has received personal compensation in the range of $500-$4,999 for serving as a Speaker with EMD Serono.
Craig S. Moore, PhD (Memorial University of Newfoundland) Dr. Moore has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Samuel Ludwin, MD (Kingston General Hospital) No disclosure on file
No disclosure on file
Alexandre Prat, MD (CHUM Hopital Norte Dame/ Dept of Neurology) The institution of Dr. Prat has received research support from CIHR and MSSC.
Jack P. Antel, MD, FAAN (Montreal Neurologic Hospital) Dr. Antel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for sanofi, roche, biogen, wave,nervgen. The institution of Dr. Antel has received research support from Novartis canada bristol myers squib. Dr. Antel has a non-compensated relationship as a past president with ACTRIMS that is relevant to AAN interests or activities.
Amit Bar-Or, MD, FRCPC (University of Pennsylvania) Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merk/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for cabaletta. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. The institution of Dr. Bar-Or has received research support from Novartis. The institution of Dr. Bar-Or has received research support from Biogen. The institution of Dr. Bar-Or has received research support from Roche/Genentech.